O7P Share Price Performance
€0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
NeuBase Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
O7P Community Narratives
There are no narratives available yet.
Recent O7P News & Updates
NeuBase Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -6.55
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
NeuBase Therapeutics, Inc. Competitors
Snowflake Analysis
About O7P
- Founded
- n/a
- Employees
- 37
- CEO
- WebsiteView website
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington’s disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 0.8%
- 3 Months: 8.3%
- 1 Year: 17.8%
- Year to Date: 15.4%
The Utilities sector gained 3.1% while the market remained flat over the last week. As for the longer term, the market has risen 18% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›